logo-loader

Circassia Pharmaceuticals PLC

Receive alerts
Market:
LSE
Market Cap:
£60.66 m
Price
16.17 GBX
Change
-2.01%
52 weeks high
77.10
52 weeks low
13.25

In brief

Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States. We are expanding our commercial platform in China, and are working to expand our portfolio through in-licensing, partnering or acquisition. 

https://www.circassia.com/company/

Deep dive We explore the investor case for growth companies

Snapshot

City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”

Insight Widest with the analysis, Proactive gives perspectives that others don't.